Peter Kowey, MD, Lankenau Heart Institute cardiologist and Lankenau Institute for Medical Research (LIMR) resident faculty member and director of the Center for Clinical Cardiology, was a member of the steering committee that designed a cardiology study, Phase IIb Study of Vanoxerine Shows Strong Safety and Statistically Significant Efficacy for Treatment of Atrial Fibrillation, presented recently at the American Heart Association Scientific Sessions in Dallas. The study indicated that Vanoxerine has proven to be safe and effective so far in the trials and will continue to be tested in its next phase of clinical development. Dr. Kowey is an advisory board member and consultant to ChanRX, the pharmaceutical company developing Vanoxerine.
In commenting on the study, Dr. Kowey said, “Atrial fibrillation affects millions of patients in the U.S. annually, causing substantial morbidity. Currently, drugs that correct the arrhythmia are inadequate and carry safety risks including life threatening arrhythmias, long-term toxicity and liver failure. Both the patients with this condition and the physicians treating them could benefit greatly from a drug that could safely treat this arrhythmia.”
As one of the top-performing cardiovascular medicine and surgery programs in the country, the Lankenau Heart Institute provides world-class, innovative care to patients with heart disease at every stage. With multiple hospitals and community practices throughout the Philadelphia region—including the Heart Pavilion at Lankenau Medical Center—the team of cardiologists, cardiovascular surgeons and subspecialists seamlessly integrates prevention, diagnostics, treatment, rehabilitation and chronic disease management into one uncompromising service line that delivers life-saving treatments with life-changing outcomes.
Lankenau Medical Center, a member of Main Line Health, is recognized as a national leader in advancing new options to diagnose and treat illness, protect against disease and save lives. Located on a 93-acre campus just outside of Philadelphia, Lankenau Medical Center is a 389-bed, not-for-profit teaching hospital that includes one of the nation’s leading cardiovascular centers; the Lankenau Institute for Medical Research, one of the few freestanding hospital-associated research centers in the nation; and the Annenberg Conference Center for Medical Education, that trains over 100 new physicians each year through nationally ranked residency and fellowship programs. Lankenau has received both regional and national recognition for its excellence in providing state-of-the-art, quality care. Lankenau Medical Center has been named among the top 10 hospitals in Pennsylvania and top five in the Philadelphia metro area in U.S. News & World Report’s Best Hospitals 2016–2017, and was ranked as high-performing in four specialties: gastroenterology and GI surgery, geriatrics, orthopedics and pulmonology. Lankenau was also ranked as high performing in all nine of the Common Core specialty areas that the publication analyzes, including: abdominal aortic aneurysm repair, aortic valve surgery, COPD, colon cancer surgery, congestive heart failure, heart bypass surgery, hip replacement, knee replacement and lung cancer surgery. Lankenau has achieved The Joint Commission’s Gold Seal of Approval for stroke care and breast cancer care and is one of the nation’s Top Performing Hospitals for heart attack, heart failure, pneumonia and surgical care. Lankenau has also been ranked for multiple years as one of the top 50 cardiovascular hospitals in the nation by Truven Health Analytics. Lankenau has also earned the highest distinction for excellence in nursing care, the American Nurses Credentialing Center Magnet® designation.
© 2016 Main Line Health